Ash Jayagopal
Directeur Technique/Scientifique/R&D chez OCUPHIRE PHARMA, INC.
Fortune : 131 880 $ au 31/05/2024
Profil
Ash Jayagopal is currently the Chief Scientific & Development Officer at Ocuphire Pharma, Inc. He is also the President of the ASSociation For Ocular Pharmacology & Therapeutics.
Previously, he held the position of Executive Director-Discovery Medicine at Kodiak Sciences, Inc. from 2019 to 2021.
Prior to that, he was the Head-Ophthalmology Discovery & Biomarkers at F.
Hoffmann-La Roche Ltd.
from 2015 to 2019.
He also served as an Assistant Professor at Vanderbilt University Medical Center from 2008 to 2015.
Additionally, he is the Chief Scientific Officer at Opus Genetics, Inc. from 2021 to 2024.
Dr. Jayagopal holds an MBA from Kelley School of Business and a doctorate from Vanderbilt University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCUPHIRE PHARMA, INC.
0,30% | 22/05/2024 | 78 500 ( 0,30% ) | 131 880 $ | 31/05/2024 |
Postes actifs de Ash Jayagopal
| Sociétés | Poste | Début |
|---|---|---|
| OCUPHIRE PHARMA, INC. | Directeur Technique/Scientifique/R&D | 14/02/2024 |
| ASSociation For Ocular Pharmacology & Therapeutics | President | - |
Anciens postes connus de Ash Jayagopal
| Sociétés | Poste | Fin |
|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Directeur Technique/Scientifique/R&D | 01/01/2024 |
| KODIAK SCIENCES INC. | Corporate Officer/Principal | 01/01/2021 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/2019 |
Vanderbilt University Medical Center
 Vanderbilt University Medical Center Hospital/Nursing ManagementHealth Services Vanderbilt University Medical Center operates as a academic medical center. It provides patient care, research, and biomedical education services. The company is headquartered in Nashville, TN. | Corporate Officer/Principal | 01/01/2015 |
Formation de Ash Jayagopal
| Kelley School of Business | Masters Business Admin |
| Vanderbilt University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KODIAK SCIENCES INC. | Health Technology |
| OCUPHIRE PHARMA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Vanderbilt University Medical Center
Vanderbilt University Medical Center Hospital/Nursing ManagementHealth Services Vanderbilt University Medical Center operates as a academic medical center. It provides patient care, research, and biomedical education services. The company is headquartered in Nashville, TN. | Health Services |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
| ASSociation For Ocular Pharmacology & Therapeutics |
